Sep 14, 2026 · 13 min · 9 segments
This week's episode focuses on metastatic non-small cell lung cancer - the quickly growing and changing systemic therapy landscape, including traditional chemotherapy, immunotherapy, and targeted…
So what do we test for now in stage 4 non-small cell lung
cancer? Everything.
Just everything.
For all non-squamous, and you can consider for squamous, the panel should cover at least 80%.
And one caveat, plasma circulating tumor DNA is a complementary tool, especially when tissue is scarce or if you need the speed of that, but it does not replace tissue.
And so what are the details of the targetable mutations?
So it still holds true that if you find a targetable driver, you go after that first line.
You think about that over chemo and IO.
So what do we test for now in stage 4 non-small cell lung
cancer? Everything.
Just everything.
For all non-squamous, and you can consider for squamous, the panel should cover at least 80%.
And one caveat, plasma circulating tumor DNA is a complementary tool, especially when tissue is scarce or if you need the speed of that, but it does not replace tissue.
And so what are the details of the targetable mutations?
So it still holds true that if you find a targetable driver, you go after that first line.
You think about that over chemo and IO.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
